Clinical Trials Logo

Clinical Trial Summary

The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression


Clinical Trial Description

Glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable Patient prognosis differs considerably within the different World Health Organization (WHO) grades, poorest prognosis for patients with the grade IV tumour- the glioblastoma multiform (GBM).

Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen.

Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in malignant transformation of low to high by inhibiting the proliferation of T cell Study the role of fibrinogen-like protein2 on Immunosuppression and progression ,free survival and overall survival in high grade glioma ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04113278
Study type Observational
Source Assiut University
Contact samir shehata, professor
Phone 01222302375
Email Samir-eid@Hotmail.com
Status Not yet recruiting
Phase
Start date November 1, 2019
Completion date September 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04390906 - A Study of Cognitive Changes in Patients Receiving Brain Radiation
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Enrolling by invitation NCT06391294 - Neuronal and Network Mechanisms of Electrocortical Stimulation
Active, not recruiting NCT05832450 - Predictive Model to Calculate the Risk of RBC Transfusion in Elective Brain Tumours Resections (TScoreBTR)
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT03067467 - Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
Recruiting NCT04468919 - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit N/A
Recruiting NCT04742231 - Handheld Dynamometer During Awake Craniotomy Pilot N/A
Recruiting NCT04725032 - Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials N/A
Recruiting NCT03542409 - Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas N/A
Active, not recruiting NCT04165941 - Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Phase 1
Completed NCT03731455 - WISE Cortical Strip for Intraoperative Neurophysiological Monitoring N/A
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1